Q2 2024 EPS Estimates for Heron Therapeutics, Inc. (NASDAQ:HRTX) Increased by Analyst

Heron Therapeutics, Inc. (NASDAQ:HRTX - Free Report) - Equities researchers at Northland Capmk lifted their Q2 2024 earnings per share estimates for shares of Heron Therapeutics in a research report issued to clients and investors on Wednesday, May 8th. Northland Capmk analyst C. Byrnes now anticipates that the biotechnology company will post earnings of ($0.04) per share for the quarter, up from their prior estimate of ($0.09). The consensus estimate for Heron Therapeutics' current full-year earnings is ($0.24) per share. Northland Capmk also issued estimates for Heron Therapeutics' Q3 2024 earnings at ($0.03) EPS, Q4 2024 earnings at ($0.01) EPS, FY2024 earnings at ($0.10) EPS and FY2025 earnings at ($0.05) EPS.

Heron Therapeutics (NASDAQ:HRTX - Get Free Report) last announced its quarterly earnings results on Tuesday, March 12th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.15) by $0.08. The company had revenue of $34.23 million for the quarter, compared to the consensus estimate of $30.98 million.

Several other equities analysts have also recently commented on the stock. Capital One Financial initiated coverage on shares of Heron Therapeutics in a research report on Tuesday, April 23rd. They set an "overweight" rating and a $6.00 target price on the stock. StockNews.com upgraded Heron Therapeutics from a "sell" rating to a "hold" rating in a research note on Tuesday, January 16th. Finally, Needham & Company LLC reiterated a "buy" rating and set a $5.00 target price on shares of Heron Therapeutics in a research note on Wednesday.

Heron Therapeutics Trading Down 5.8 %

Shares of HRTX traded down $0.17 during trading hours on Friday, reaching $2.77. 1,992,360 shares of the stock traded hands, compared to its average volume of 2,772,385. Heron Therapeutics has a 52 week low of $0.50 and a 52 week high of $3.22. The company has a market cap of $417.26 million, a price-to-earnings ratio of -3.22 and a beta of 1.73. The stock has a fifty day simple moving average of $2.73 and a 200 day simple moving average of $2.09.

Hedge Funds Weigh In On Heron Therapeutics

Several institutional investors have recently bought and sold shares of the company. Rubric Capital Management LP raised its stake in shares of Heron Therapeutics by 127.3% in the third quarter. Rubric Capital Management LP now owns 26,713,503 shares of the biotechnology company's stock valued at $27,515,000 after buying an additional 14,963,503 shares during the period. JW Asset Management LLC lifted its holdings in Heron Therapeutics by 9.1% during the third quarter. JW Asset Management LLC now owns 2,407,418 shares of the biotechnology company's stock valued at $2,480,000 after purchasing an additional 200,000 shares during the last quarter. Orchard Capital Management LLC boosted its position in Heron Therapeutics by 4.7% during the fourth quarter. Orchard Capital Management LLC now owns 2,243,426 shares of the biotechnology company's stock worth $3,814,000 after purchasing an additional 100,603 shares during the period. Monaco Asset Management SAM increased its stake in shares of Heron Therapeutics by 219.5% in the fourth quarter. Monaco Asset Management SAM now owns 2,226,475 shares of the biotechnology company's stock worth $3,785,000 after purchasing an additional 1,529,567 shares in the last quarter. Finally, Tejara Capital Ltd raised its position in shares of Heron Therapeutics by 28.6% in the third quarter. Tejara Capital Ltd now owns 2,109,681 shares of the biotechnology company's stock valued at $2,173,000 after purchasing an additional 469,548 shares during the period. Hedge funds and other institutional investors own 80.01% of the company's stock.

About Heron Therapeutics

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.